Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 475 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Cancer in My Community: The 3 Ways People Access Cancer Care... February 2, 2023 Survivors of Childhood Cancer are at Excess Risk of Late Mortality... April 21, 2023 Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... September 10, 2025 Cancer Research UK thanks Tania Bryer for a decade of fundraising... April 19, 2022 Load more HOT NEWS New reports show staff shortages continue to hold back cancer care Identical Twins Find Strength in Shared Breast Cancer Battle After Being... What if we count all that still remains? Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and...
